DNA Methylation Readers and Cancer: Mechanistic and Therapeutic Applications

Overview

Journal Front Oncol

Specialty Oncology

Date 2019 Jun 28

PMID 31245293

Citations 58

Authors

Niaz Mahmood

Shafaat A Rabbani

Affiliations

Soon will be listed here.

Abstract

DNA methylation is a major epigenetic process that regulates chromatin structure which causes transcriptional activation or repression of genes in a context-dependent manner. In general, DNA methylation takes place when methyl groups are added to the appropriate bases on the genome by the action of "writer" molecules known as DNA methyltransferases. How these methylation marks are read and interpreted into different functionalities represents one of the main mechanisms through which the genes are switched "ON" or "OFF" and typically involves different types of "reader" proteins that can recognize and bind to the methylated regions. A tightly balanced regulation exists between the "writers" and "readers" in order to mediate normal cellular functions. However, alterations in normal methylation pattern is a typical hallmark of cancer which alters the way methylation marks are written, read and interpreted in different disease states. This unique characteristic of DNA methylation "readers" has identified them as attractive therapeutic targets. In this review, we describe the current state of knowledge on the different classes of DNA methylation "readers" identified thus far along with their normal biological functions, describe how they are dysregulated in cancer, and discuss the various anti-cancer therapies that are currently being developed and evaluated for targeting these proteins.

Citing Articles

Epigenetic modulators provide a path to understanding disease and therapeutic opportunity.

Honer M, Ferman B, Gray Z, Bondarenko E, Whetstine J Genes Dev. 2024; 38(11-12):473-503.

PMID: 38914477 PMC: 11293403. DOI: 10.1101/gad.351444.123.

Patel D, McElroy J, Weng D, Sahar K, Reisinger S, Freudenheim J Sci Rep. 2024; 14(1):14280.

PMID: 38902313 PMC: 11190195. DOI: 10.1038/s41598-024-65027-y.

UHRF2 accumulates in early G-phase after serum stimulation or mitotic exit to extend G and total cell cycle length.

Wang X, Lu H, Sprangers G, Hallstrom T Cell Cycle. 2024; 23(5):613-627.

PMID: 38752903 PMC: 11135863. DOI: 10.1080/15384101.2024.2353553.

DNA Methylation Machinery in Gastropod Mollusks.

Haidar L, Georgescu M, Draghici G, Banatean-Dunea I, Nica D, Serb A Life (Basel). 2024; 14(4).

PMID: 38672807 PMC: 11050768. DOI: 10.3390/life14040537.

Methyl-CpG binding domain protein 2 (Mbd2) drives breast cancer progression through the modulation of epithelial-to-mesenchymal transition.

Mahmood N, Arakelian A, Szyf M, Rabbani S Exp Mol Med. 2024; 56(4):959-974.

PMID: 38556549 PMC: 11058268. DOI: 10.1038/s12276-024-01205-2.

References

Bhattacharya S, Ramchandani S, Cervoni N, Szyf M . A mammalian protein with specific demethylase activity for mCpG DNA. Nature. 1999; 397(6720):579-83. DOI: 10.1038/17533. View

Bellacosa A, Cicchillitti L, Schepis F, Riccio A, Yeung A, Matsumoto Y . MED1, a novel human methyl-CpG-binding endonuclease, interacts with DNA mismatch repair protein MLH1. Proc Natl Acad Sci U S A. 1999; 96(7):3969-74. PMC: 22404. DOI: 10.1073/pnas.96.7.3969. View

Daniel J, Reynolds A . The catenin p120(ctn) interacts with Kaiso, a novel BTB/POZ domain zinc finger transcription factor. Mol Cell Biol. 1999; 19(5):3614-23. PMC: 84161. DOI: 10.1128/MCB.19.5.3614. View

Hendrich B, Abbott C, Mcqueen H, Chambers D, Cross S, Bird A . Genomic structure and chromosomal mapping of the murine and human Mbd1, Mbd2, Mbd3, and Mbd4 genes. Mamm Genome. 1999; 10(9):906-12. DOI: 10.1007/s003359901112. View

Zhang Y, Ng H, Erdjument-Bromage H, Tempst P, Bird A, Reinberg D . Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev. 1999; 13(15):1924-35. PMC: 316920. DOI: 10.1101/gad.13.15.1924. View

Ng H, Zhang Y, Hendrich B, Johnson C, Turner B, Erdjument-Bromage H . MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat Genet. 1999; 23(1):58-61. DOI: 10.1038/12659. View

Amir R, Van den Veyver I, Wan M, Tran C, Francke U, Zoghbi H . Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999; 23(2):185-8. DOI: 10.1038/13810. View

Ohminami H, Yasukawa M, Fujita S . HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood. 1999; 95(1):286-93. View

Bader S, Walker M, Hendrich B, Bird A, Bird C, Hooper M . Somatic frameshift mutations in the MBD4 gene of sporadic colon cancers with mismatch repair deficiency. Oncogene. 2000; 18(56):8044-7. DOI: 10.1038/sj.onc.1203229. View

10.

Hopfner R, Mousli M, Jeltsch J, Voulgaris A, Lutz Y, Marin C . ICBP90, a novel human CCAAT binding protein, involved in the regulation of topoisomerase IIalpha expression. Cancer Res. 2000; 60(1):121-8. View

11.

Jones M, Hamana N, Nezu J, SHIMANE M . A novel family of bromodomain genes. Genomics. 2000; 63(1):40-5. DOI: 10.1006/geno.1999.6071. View

12.

Scharnhorst V, Menke A, Attema J, Haneveld J, Riteco N, van Steenbrugge G . EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity. Oncogene. 2000; 19(6):791-800. DOI: 10.1038/sj.onc.1203390. View

13.

Gao L, Bellantuono I, Elsasser A, Marley S, Gordon M, Goldman J . Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood. 2000; 95(7):2198-203. View

14.

Zhang W, Geiman D, Shields J, Dang D, Mahatan C, Kaestner K . The gut-enriched Kruppel-like factor (Kruppel-like factor 4) mediates the transactivating effect of p53 on the p21WAF1/Cip1 promoter. J Biol Chem. 2000; 275(24):18391-8. PMC: 2231805. DOI: 10.1074/jbc.C000062200. View

15.

Magdinier F, Billard L, Wittmann G, Frappart L, Benchaib M, Lenoir G . Regional methylation of the 5' end CpG island of BRCA1 is associated with reduced gene expression in human somatic cells. FASEB J. 2000; 14(11):1585-94. DOI: 10.1096/fj.14.11.1585. View

16.

BOEKE J, Ammerpohl O, Kegel S, Moehren U, Renkawitz R . The minimal repression domain of MBD2b overlaps with the methyl-CpG-binding domain and binds directly to Sin3A. J Biol Chem. 2000; 275(45):34963-7. DOI: 10.1074/jbc.M005929200. View

17.

Yan S, Fujita T, Lu J, Okada K, Shan Zou Y, Mackman N . Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat Med. 2000; 6(12):1355-61. DOI: 10.1038/82168. View

18.

Foster K, Frost A, Lin C, Engler J, Grizzle W, Ruppert J . Increase of GKLF messenger RNA and protein expression during progression of breast cancer. Cancer Res. 2000; 60(22):6488-95. View

19.

Holliday R, Pugh J . DNA modification mechanisms and gene activity during development. Science. 1975; 187(4173):226-32. View

20.

Hendrich B, Guy J, Ramsahoye B, WILSON V, Bird A . Closely related proteins MBD2 and MBD3 play distinctive but interacting roles in mouse development. Genes Dev. 2001; 15(6):710-23. PMC: 312657. DOI: 10.1101/gad.194101. View